Compass Therapeutics (CMPX) Other Working Capital Changes (2019 - 2026)

Compass Therapeutics has disclosed Other Working Capital Changes across 8 years of filings, most recently posting $87000.0 for Q1 2026.

• Other Working Capital Changes for Q1 2026 came in at $87000.0, up 134.39% year-over-year; the trailing twelve-month figure through Mar 2026 was -$4.8 million (down 98.5% YoY), and the FY2025 annual result was -$5.1 million, down 320.38% from the prior year.
• Other Working Capital Changes came in at $87000.0 for Q1 2026 at Compass Therapeutics, up from -$4.8 million in the prior quarter.
• In the past five years, Other Working Capital Changes ranged from a high of $5.0 million in Q2 2024 to a low of -$6.5 million in Q3 2024.
• The 5-year median for Other Working Capital Changes is -$97000.0 (2022), against an average of -$502941.2.
• Peak annual rise in Other Working Capital Changes reached 985.31% in 2023, while the deepest fall reached 4755.67% in 2023.
• Compass Therapeutics' Other Working Capital Changes stood at -$463000.0 in 2022, then jumped by 985.31% to $4.1 million in 2023, then sank by 114.08% to -$577000.0 in 2024, then slumped by 729.29% to -$4.8 million in 2025, then soared by 101.82% to $87000.0 in 2026.
• The last three Other Working Capital Changes figures came in at $87000.0 (Q1 2026), -$4.8 million (Q4 2025), and -$37000.0 (Q3 2025), per Business Quant data.